(Q35166950)

6 August 2017

1 reference

17 December 2020

Mechanisms of resistance to RAF inhibitors in melanoma (English)

1 reference

antineoplastic resistance

6 August 2017

1 reference

26 October 2020

1 reference

17 December 2020

1 reference

28 September 2019

1 reference

26 October 2020

1 reference

25 November 2020

1 reference

17 December 2020

Andrew E Aplin

1

1 reference

6 August 2017

Fred M Kaplan

series ordinal

2

1 reference

6 August 2017

Yongping Shao

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

19 May 2011

1 reference

Journal of Investigative Dermatology

6 August 2017

1 September 2011

15 references

12 March 2019

19 March 2019

24 March 2019

3 April 2019

17 June 2019

2 August 2019

20 August 2019

17 September 2019

28 September 2019

7 November 2019

20 November 2019

18 December 2019

26 October 2020

25 November 2020

17 December 2020

16 references

6 August 2017

12 March 2019

19 March 2019

24 March 2019

3 April 2019

17 June 2019

2 August 2019

20 August 2019

17 September 2019

28 September 2019

7 November 2019

20 November 2019

18 December 2019

26 October 2020

25 November 2020

17 December 2020

131

1 reference

6 August 2017

1817-1820

1 reference

6 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2011.147

6 August 2017

0 references

cites work

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Narrative review: BRAF opens the door for therapeutic advances in melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

MEK1 mutations confer resistance to MEK and B-RAF inhibition

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

New insight into BRAF mutations in cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Mutations of the BRAF gene in human cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Melanoma--an unlikely poster child for personalized cancer therapy.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

Loss of Rb overrides the requirement for ERK activity for cell proliferation

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156870

The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21593776

12 December 2020

inferred from PubMed ID database lookup

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21593776

12 December 2020

inferred from PubMed ID database lookup

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FJID.2011.147

7 January 2021

inferred from DOI database lookup

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FJID.2011.147

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/JID.2011.147

1 reference

6 August 2017

1 reference

6 August 2017

1 reference